Home Featured Page 161

Featured

Latest

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines are reduced to standard protocols

A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and Ketamine Therapy

Pα+ Psychedelic Bulletin #223: Ibogaine Advocates Court Trump, via Rogan; Compass Launches Provider Training Grants; Therapeutic Alliance Debate Reignites

Psychedelic Funding Update: Q1 2026

Optimi Health Enters Into International Collaborative Research and Supply Agreement With...

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global...

Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S....

PT351 – Seth Rosenberg – The Trauma In Being Arrested and...

PsyBio Therapeutics Reports Second Quarter 2022 Financial Results

Wesana Announces Second Quarter 2022 Financial Results

Psychedelic Bulletin #116 – Ketamine Combo Co. Scores $10m; DEA Drops...

MindMed Completes 1-for-15 Reverse Share Split

PT350 – Jim Gilligan – Psilocybin and Accessing the “Off” Switch...

EDITOR PICKS

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines...

A Practitioner Statement on the Responsible Development of Ibogaine in the...

Dr. Michael Alpert and Peter Alberding – ALS, Existential Distress, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.